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ScienceDirectIn recent years our understanding of amyloid structure has
been revolutionised by innovations in cryo-electron
microscopy, electron diffraction and solid-state NMR. These
techniques have yielded high-resolution structures of fibrils
isolated from patients with neurodegenerative disease, as well
as those formed from amyloidogenic proteins in vitro. The
results not only show the expected cross-b amyloid structure,
but also reveal that the amyloid fold is unexpectedly diverse
and complex. Here, we discuss this diversity, highlighting
dynamic regions, ligand binding motifs, cavities, non-protein
components, and structural polymorphism. Collectively, these
variations combine to allow the generic amyloid fold to be
realised in three dimensions in different ways, and this diversity
may be related to the roles of fibrils in disease.
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Introduction
Amyloid is a conformational state that can be achieved by
most (if not all) proteins [1]. Protein sequences harbor
the information necessary to enable them to fold
into their native, functional 3D structures [2] or, for
intrinsically disordered proteins (IDP), to remain dynam-
ically unstructured [3]. However, proteins also contain
sequences capable of forming an alternative structure(s)
known as the ‘amyloid fold’ [4]. Upon cellular or physical
stress, by a mechanism that is kinetically complex [5] and
difficult to characterise structurally [6], one or more of
these ‘amyloid-prone regions (APR)’, can rearrange to
form b-strands, which stack in layers oriented perpendic-
ular to the fibril’s long axis to generate the ‘amyloid fold’
(Figure 1a) [1]. These b-strands and their interconnect-
ing loops constitute the ‘amyloid core’. The repeating
nature of amyloid cores, involving extensive mainchain
hydrogen bonding between adjacent b-strands within thewww.sciencedirect.com stacked layers (Figure 1b1), and close interdigitation of
sidechains (Figure 1b2), results in a fibril structure that is
enormously stable both thermodynamically [7] and
mechanically [8]. Indeed this stability can far exceed that
of the original native fold of the protein, highlighting the
physico-chemical knife-edge of cellular life because of
the metastable nature of their proteomes [7]. Fascinat-
ingly, despite their high stability, fibrils are dynamic, with
monomers and/or oligomers dissociating from their ends
[9,10], while the surface of the fibrils can act as a potent
site for secondary nucleation, catalysing the formation of
oligomers and new fibrils [11,12].
The molecular mechanism(s) by which IDPs and initially
folded amyloidogenic precursors rearrange into an
amyloid core structure and stack into molecular layers
is not well understood. However, it is generally accepted
that this feat is accomplished via the formation of
transient non-native monomeric and oligomeric species
[6,13]. The transient and dynamic nature of such species
has limited the characterisation of their structures and our
understanding of the molecular basis of the cytotoxicity
often associated to amyloid formation [14,15].
Here we review recent advances in our understanding of
the amyloid fold. We describe the interactions that create
the fibril core, as well as less well-ordered and dynamic
regions of the amyloid fold. We also discuss differences
between fibril structures formed in vitro and in vivo, and
how structural polymorphism may rationalise disease
phenotype. Finally, we highlight the need to combine
information from multiple structural, biophysical, and
cellular techniques, including information gained from
in vitro and in vivo analyses, to understand amyloid
formation and disease.
Updating our understanding of the amyloid
fold
One sequence, many structures
The first high resolution structural information about
amyloid came from fibrils assembled from synthetic
peptides [16–19]. These structures revealed the first atomic
resolution details of the stacking of b-strands in the cross-b
architecture, which had been visualised at lower resolution
some 50 years before [20]. The first structures of amyloid
fibrils from intact proteins at atomic/near-atomic resolution
were obtained from fibrils assembled in vitro of the amyloi-
dogenic IDPs Ab40, Ab42, amylin and a-synuclein using
solid state NMR (ssNMR) [21–25]. The recent revolution in
cryo-EM has now expanded this repertoire to fibrils formed
in vitro or extracted ex vivo from b2-microglobulin (b2m),
mouse and human serum Amyloid A (AA), Light Chain (LC)Current Opinion in Structural Biology 2020, 60:7–16
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Updating the amyloid fold. (a) Schematic of the cross-b fold viewed from (1) side and (2) cross-section, representing the stacking of molecular
layers perpendicular to the long axes of the amyloid fibrils. (b) Detail of the structural elements observed in amyloid cores highlighting (1) in-
register parallel b-sheets [30], (2) ‘dry’ steric zippers [29], (3) sidechain-mainchain loop hydrogen bonding [37], (4) polar zippers [26], (5) buried
salt-bridges [36], (6) structured solvent molecules [27], (7) polar and apolar channels (green and purple arrows, respectively) [36], (8) cofactors
(blue density) [27] and (9) multi-molecular layer interactions between central layer ‘L’ (blue) and the adjacent layers above and below (gold) [35].
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a-synuclein and Ab42, [26
,27,28,29,30,31–33,
34,35,36,37]. These results show that the same protein
sequence can adopt different amyloid structures, leading to
more fibril structures than sequences (45 amyloid fibril
structures from full proteins and IDPs are currently depos-
ited in the pdb). For a-synuclein, four distinct polymorphs
have been solved by cryo-EM [31,32,33,34] and one
structure of a single protofibril by ssNMR [23]. For Tau
three different neurodegenerative diseases result in fibrils
with distinct, disease-specific structures, all of which
are different from the structures formed in vitro in the
presence of heparin [26,27,28,38]. Whether this differ-
ence between in vitro and in vivo fibril structures is found for
other amyloid proteins remains an important, open question.
A convoluted amyloid fold
The structures of amyloid fibrils solved by ssNMR [21–24]
and cryo-EM [26,27,28,29,30,31–33,34,35,36,37]
have revealed that a wide variety of interactions can stabi-
lise an amyloid core. While all of these structures have
canonical cross-b amyloid folds, their structures are more
complicated and diverse than originally anticipated. For
amyloid precursors that are initially folded, assembly into
the amyloid core requires wholesale rearrangement of
the polypeptide chain and sometimes reassignment of
the secondary structure elements [36]. As expected,
extensive backbone hydrogen bonding between b-strands
is observed in these new fibril structures (Figure 1b1), but
the topologies of the structural elements that comprise the
amyloid core is more complex than those seen in fibrils
formed from short peptide fragments [16,18,39,40]. The
b-sheets are not, in general, formed from homotypic ‘dry
steric zipper’ interactions in which two copies of the same
sequence form sidechain-sidechain interactions between
the b-sheets [18,41]. Such zippers are observed in fibrils
formed from intact proteins, but in the interfaces formed
between protofilaments (Figure 1b2) [28,29,32]. The
current list of interactions and structural motifs known
to stabilise the amyloid core (Figure 1b) also includes
sidechain-mainchain and sidechain-sidechain hydrogen
bonding from loops that interconnect b-strands
(Figure 1b3), tight interdigitation of polar and charged side
chains (named here ‘polar zippers’) (Figure 1b4), buried
salt bridges (Figure 1b5), interactions with solvent
(Figure 1b6) [27], and both polar [36] and apolar
[27,31,36] internal channels (Figure 1b7). In the latter
case, an un-assigned electron density inside the apolar
channel of tau filaments isolated from patiens that
suffer chronic traumatic encephalopathy suggests that
non-proteinaceous aliphatic molecules may participate in
this amyloid core (Figure 1b8) [27]. Finally, a given
molecular layer (L), may make interactions with the layer
above (L + 1),below(L  1),oreven beyondits immediate
neighbours (L + 2, L  2, etc). Such interactions also
stabilise the amyloid core (Figure 1b9) [35].www.sciencedirect.com Different forms of fibril polymorphism
The biological relevance of amyloid polymorphism
has been extensively documented for several amyloid
diseases [1]. Fibrils created from the same precursor
have been shown to display different structures in differ-
ent diseases [26,27,28], different seeding characteris-
tics [42], different rates of spread [43], and distinct
patterns of neuropathology [44,45]. Cryo-EM has a
major advantage for structural characterisation of fibril
polymorphs since each structure can (in principle) be
determined independently for each co-populating
polymorph, as long as sufficient images of each type
can be obtained. Polymorphism can take different forms.
Firstly (type 1), it can involve different packing
arrangements of the same protofibril, as was observed
for amyloidogenic peptides of transthyretin (TTR) [40]
and immunoglobulin LC l-1 (Figure 2a) [46], as well as
for entire proteins such as b2m (Figure 2b) [30
]. In some
cases, this type of polymorphism can involve
subtle changes in the contact angle or arrangement of
interactions between protofilaments, exemplified by the
difference in Paired Helical Filaments (PHF) and
Straight Filaments (SF) of Tau fibrils analysed from
Alzheimer’s patients (Figure 2c) [28], and in early
models of fibril structures of Ab40 observed by ssNMR
(Figure 2d) [19,22]. In other cases, this polymorphism can
involve fibrils comprised of different numbers of
protofilaments, such as in the narrow (NPF) and wide
(WPF) filaments observed in Tau fibrils from Pick’s
disease (Figure 2e) [26]. A second type of polymorphism
(type 2) can occur when a common structure is adopted by
one region of a protein sequence, while different
structures are adopted by other regions. This is observed
in the ‘Rod’ and ‘Twister’ polymorphs of a-synuclein
fibrils (Figure 2f) [32] and in Serum Amyloid A (AA) fibrils
[35] (Figure 2g). A third type of polymorphism (type 3)
combines types 1 (different packing of protofilaments)
and type 2 (partial common fold) and has been observed
for Ab42 in structures elucidated by cryo-EM [29] and
ssNMR [24]. These structures exhibit a common fold (the
‘S motif’) that packs through different interfaces and with
different structures for the N-terminal domain
(Figure 2h). Other polymorphs of Ab42 have also been
observed in which different numbers of protofilaments
with different twists are involved [47], but it is not yet
known which molecular interactions create these
different polymorphs. The fourth (type 4), and most
drastic, kind of polymorphism occurs when both the
protofilament structure and packing interactions vary,
as observed in polymorphs of Tau fibrils formed in vitro
in the presence of heparin (Figure 2i) [38], and in fibrils
formed from fragments of TDP43 in vitro, in which three
polymorphs are observed for the same sequence segment
(Figure 2j) [48]. At least for Tau, samples from 17 patients
that suffered from two variants of the same disease
possessed fibrils with a similar fold, suggesting that a
common fibril structure could be associated with aCurrent Opinion in Structural Biology 2020, 60:7–16
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The many faces of an amyloid. Fibril polymorphs observed for (a) peptide fragments of LC l1 [46] and for the full-length proteins (b) b2m [30
], (c)
Tau in AD [28], (d) Ab40 [19,22], (e) Tau in Pick’s Disease [26
], (f) a-synuclein [32], (g) mouse and human serum AA [35], (h) Ab42 [24,29], (i) Tau
in presence of heparin [38] and (j) segments of TDP43 [48]. These fibrils were isolated ex vivo (c,e,g) or formed in vitro (a,b,d,f,h,i,j). Illustrations in
(a) and (b) are reproduced with permission [30,46].
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Amyloid is more than a rigid core. LDRs are shown on the structures of amyloid fibrils of full-length proteins formed in vitro or isolated ex vivo. The
top of each panel shows a schematic of the full-length sequence (bar) with the sequence involved in forming the ordered amyloid core in blue and
LDRs in white. The image on panels (a–h) corresponds to an orthogonal view down the fibril axis of the reported density maps contoured at two
different levels. The regions of localised disorder are shown as broad/noisy density (orange) surrounding the amyloid core density (blue) for (a) Tau
in Alzheimer’s disease [28], (b) Tau in CTE [27], (c) two polymorphs of a-synuclein [32], (d) b2m [30
], (e) IGLV6-57 derived LC amyloid [37], (f)
www.sciencedirect.com Current Opinion in Structural Biology 2020, 60:7–16
12 Folding and bindingparticular disease [49]. Yet, in all of the above cases less
abundant polymorphs could also be present, albeit in too
low a number to enable structure determination.
What drives fibril diversity is unclear. It could result from
the intrinsic properties of the polypeptide sequence; the
presence or absence of post-translational modifications;
interaction with cofactors or cellular components;
the nature of the environment (pH, ionic strength etc),
or the cell type in which amyloid is formed. That inter-
action with cofactors can modulate the abundance of
polymorphs has been shown for Tau, with heparin
inducing structurally heterogeneous fibrils, while RNA
induces structurally homogeneous fibrils [50]. Sequence
variation can also contribute to polymorphism. For
example, fibrils generated from the 3R isoform of Tau
in Pick’s disease (NPF and WPF, Figure 2e) [26] are
different to those generated by the 4R isoform in
Alzheimer’s disease (HPF and SF, Figure 2c) [28].
Dynamic regions are integral to the amyloid fold
Another remarkable characteristic of the amyloid fibril
structures determined recently is that relatively short
regions of a protein sequence form the amyloid core
[26,27,28,30,31,32,33,35,36,37], with the remaining
segments exhibiting high structural variability (Figure 3).
Disordered regions map to the termini (Figure 3a–i)
[23,24,26,27,28,32], and to internal loops/segments
of the polypeptide chain (Figure 3e) [37]. For example,
the amyloid core of Tau fibrils involves between 72 and
94 of its 441 residues, with the number of ordered amino
acids depending on the tauopathy (Figure 3a–b)
[26,27]. For a-synuclein, 40–59 of its 140 residues form
the amyloid core depending on the polymorph (Figure 3c)
[32]. Similar observations have been made for b2m (63 out
of 100 residues [30] (Figure 3d), antibody LC case 1
(77 out of 111 residues [37] (Figure 3e)), or case 2 (91 out
of 118 residues [36] (Figure 3f)), SAA from mouse
(69 out of 83 residues), and SAA from humans (53 out
of 67 residues) [35] (Figure 3g and h, respectively). We
refer to these as ‘Locally Disordered Regions’ (LDRs) to
signify their localised high structural variability. LDRs
have also been described in fibrils of Ab42, where the N-
terminal 14–15 residues, that coincide with the least
amyloidogenic regions, are not involved in the amyloid
core (Figure 3i) [24]. Similarly, the N-terminal 10 residues
of b2m are highly dynamic, with the succeeding
10 residues less so (but not organised into the amyloid
core) [30]. Finally, for the structure of a-synuclein fibrils
determined using ssNMR, three regions (1-24, 55-62
and 97-140) lack assignment [23] and this is usually
interpreted as signifying dynamic behaviour.(Figure 3 Legend Continued) GLV1-44 derived LC amyloid [36], (g) mous
fibrils determined by ssNMR [24], where regions of disorder are modeled as
used is indicated on each panel. The blue maps are countered to the recom
5 A˚ low-pass filtered of the deposited map countered to 1.75 RMS using C
Current Opinion in Structural Biology 2020, 60:7–16 LDRs are important in amyloid formation and in disease.
For example, they can kinetically define the amyloid
structures that result from aggregation [51]. Fibrils,
including their LDRs, are also known to be involved in
engaging with cellular components that regulate the
health of the cell, including molecular chaperones [52],
other proteins that contain IDRs or IDPs [53],
components of the extracellular matrix [54], biological
membranes of different type [55] or other cellular com-
ponents [56]. These dynamic regions must not be over-
looked, despite the fact that they are difficult, if not
impossible, to structurally characterise using cryo-EM
or ssNMR. Single-molecule FRET, hydrogen/deuterium
exchange, oxidative labelling and cross-linking methods
offer exciting possibilities to characterise these regions
and their interactions in vitro and in vivo in the future.
Left or right-handed, parallel or anti-parallel?
Contrary to the canonical right-handed b-sheets observed
in globular proteins, amyloid fibrils can adopt right-
handed or left-handed b-sheets, with a switch between
handedness requiring only subtle differences in the
b-strand w/c angles [57]. For example, mouse and human
AA amyloid have opposite chirality despite having 78%
sequence identity [35]. While anti-parallel b-strands
were observed in amyloidogenic fragments using X-ray
crystallography [18,41], ssNMR [16] and X-ray fibre
diffraction [58], amyloid fibrils formed from longer
precursors commonly adopt a parallel in-register structure
(Figure 1a and b1) [1]. In these structures each
molecular layer ‘L’ deviates from planarity, which allows
intermolecular interactions beyond the immediate neigh-
bouring layers ‘L + 1’ and ‘L  1’ [29,35]. The number of
molecules that can interact in this mode can span up to
10 molecular layers, as observed in human AA amyloid
(Figure 1b9) [35]. Non-planarity of the layers also confers
a subtle polarity to the fibrils because it generates
structural differences between the two fibril ends.
Amyloid structures: beyond protein
The interactions between amyloid fibrils and cofactors has
been long studied, with the list of ligands including nucleic
acids [50,59], lipids [60], metal ions [61], glycosaminogly-
cans [62], glycoproteins [63] and others (reviewed in Ref.
[54]). The consequences of these interactions include
modulation of fibril growth kinetics and fibril stability
[62,64], changes in amyloid-associated cytotoxicity [65]
and altered seeding efficiency [50]. The recent elucidation
of the structure of Tau fibrils extracted from patients with
Chronic Traumatic Encephalopaty (CTE) have provided
the first atomic-resolution information showing thate AA and (h) human AA [35]. Panel (i) shows the structure of Ab42
 loops that point away from the core. The EMD code of each map
mended level indicated for the deposited maps. The orange maps are
himeraX [72].
www.sciencedirect.com
Diverse features of the amyloid fold Gallardo, Ranson and Radford 13
Figure 4
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A combination of techniques is required to understand the amyloid fibril structure and its cellular consequences. However, the picture is still
incomplete. The missing aspects will be achieved through biochemical, biophysical and cellular investigation. Only by an integrative approach in
which in vitro, ex vivo, in situ and in vivo approaches are combined can we hope to achieve the structural, cellular and mechanistic understanding
required to fully understand the amyloid structure and to inspire biomedical progress.co-factors can be an integral part of the amyloid core
(Figure 1b8) [27].
The amyloid fold in vivo
Recent developments in Cryo-Electron Tomography
(CryoET) have started to reveal the organisation of amyloid
fibrils in situ and how fibrils can disturb cellular processes
[66,67]. Using kinetic experiments in vitro amyloid fibril
formation can be explained as a combination of elementary
mechanisms including primary/secondary nucleation,
elongation and fragmentation [68]. This has allowed
the identification of small molecules and antibodies/cha-
perones that target specific steps in amyloid assembly
[69,70]. Importantly, the finding that the same compounds
are active in vitro and in vivo, validates the utility of in vitro
observations for understanding amyloid disease. In the
same way, fluorescent oligothiophene conjugates designed
in vitro have also been used to analyse amyloid in situ and
shown to be able to differentiate conformational variants of
Ab plaques in patients with different subtypes of
Alzheimer’s disease [71].
Although extraordinary progress has been made in our
understanding of amyloid in vivo, the resolution currentlywww.sciencedirect.com possible by cryo-ET (3 to 10 nm) does not enable fibril
structure details to be visualised within cells. Hence, the
full diversity and complexity of the amyloid fold in vivo
are yet to be revealed. To complete the picture (Figure 4)
we need to improve the resolution of fibril structures in
vitro and in situ, and to employ different techniques,
in combination, to inform on different aspects of the
amyloid fold, including the functionally important
dynamic regions discussed above. We also need to
remember that oligomers also play a key role in amyloid
disease [14,15], yet structurally characterising these
species remains a hugely challenging task in vitro, and
is not possible currently in vivo.
Summary and outlook
Recent discoveries about the structure of amyloid fibrils
have shifted our understanding of the amyloid fold from
an initially simple set of structural elements, to a complex
architecture in which apolar, polar, ionic and hydrogen
bonding interactions, together with solvent and co-factor
binding, structured cores and locally disordered regions,
build the fibril. Cofactors and post-translational modifica-
tions can also have profound effects on the structure,
kinetic and thermodynamic properties of amyloid fibrilsCurrent Opinion in Structural Biology 2020, 60:7–16
14 Folding and bindingand their cellular effects. By integrating methods able to
interrogate the structured and dynamic regions of
amyloid, and exploiting the powers of cryo-EM/ET to
determine amyloid structures in vitro, ex vivo and in situ,
we will soon have a better understanding of the amyloid
fold as a whole and how this amazingly diverse, but stable
structure, affects cells. Rather than a generic and simple
amyloid fold, there is a remarkable array of amyloid
structures, each of which may uniquely contribute to
the generation of cellular dysfunction and disease.
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